UCB announced positive results from the phase 3 BE SURE study of bimekizumab in the treatment of adults with moderate-to-severe plaque psoriasis compared with adalimumab.
Adalimumab 0.8 mg/kg every other week was effective in a population of children and adolescents affected by moderate to severe plaque psoriasis, results of a real-life clinical experience show.
The five-year incidence rate of joint surgery in psoriatic arthritis patients is twice as high as in the general population, and this rate has remained steady over time.
The FDA has approved RediTrex (methotrexate injection; Cumberland) for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis, who are intolerant of or had an inadequate response to first-line therapy.
Treatment with biologics for psoriasis is not the same for men and women, a study shows, and may explain why women tend toward earlier discontinuation with biologic treatment.
In this study, patients with psoriasis appeared to have an increased risk for cancer incidence and cancer-related mortality involving a range of site-specific cancers.
Pustular psoriasis linked to arthritis onset two years earlier; increased delay seen for plaque psoriasis
Researchers compared the association of potential risk factors for the development of psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis.
Researchers assessed the effect of uveitis, psoriasis, and inflammatory bowel disease on disease activity and functional status in a population-based cohort of patients with axial spondyloarthritis.
Bimekizumab (UCB), an investigational treatment for moderate-to-severe plaque psoriasis, met its two primary end points in a second phase 3 trial.